|Up a level|
Bygum, Anette and Fagerberg, Christina R. and Clemmensen, Ole J. and Fiebig, Britta and Hafner, Christian (2011) Systemic epidermal nevus with involvement of the oral mucosa due to FGFR3 mutation. BMC medical genetics 12, p. 79.
Hafner, Christian and Hartmann, Arndt and van Oers, Johanna M. M. and Stoehr, Robert and Zwarthoff, Ellen C. and Hofstaedter, Ferdinand and Landthaler, Michael and Vogt, Thomas (2007) FGFR3 mutations in seborrheic keratoses are already present in flat lesions and associated with age and localization. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 20 (8), pp. 895-903.
Hafner, Christian and López-Knowles, Elena and Luis, Nuno M. and Toll, Agustí and Baselga, Eulàlia and Fernández-Casado, Alex and Hernández, Silvia and Ribé, Adriana and Mentzel, Thomas and Stoehr, Robert and Hofstaedter, Ferdinand and Landthaler, Michael and Vogt, Thomas and Pujol, Ramòn M. and Hartmann, Arndt and Real, Francisco X. (2007) Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. Proceedings of the National Academy of Sciences of the United States of America: PNAS 104 (33), pp. 13450-13454.
Hafner, Christian and Landthaler, Michael and Vogt, Thomas (2006) Stroma-targeted palliative tumor therapy with biomodulators. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 4 (3), 242-253; quiz 254.
Hafner, Christian and van Oers, Johanna M. M. and Vogt, Thomas and Landthaler, Michael and Stoehr, Robert and Blaszyk, Hagen and Hofstaedter, Ferdinand and Zwarthoff, Ellen C. and Hartmann, Arndt (2006) Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. The Journal of clinical investigation: JCI 116 (8), pp. 2201-2207.
Vogt, Thomas and Hafner, Christian and Bross, Klaus and Bataille, Frauke and Jauch, Karl-Walter and Berand, Anna and Landthaler, Michael and Andreesen, Reinhard and Reichle, Albrecht (2003) Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer 98 (10), pp. 2251-6.